Sang Hoon Ahn, M.D., Kwang-Hyub Han, M.D., Young Hoon Youn, M.D.,Myoung Hwan Kim, M.D.,
Kun Hoon Song, M.D., Kwan Sik Lee, M. D., Chae Yoon Chon, M.D., Young Myoung Moon, M.D.,
Do Yun Lee, M.D.* and Jong Tae Lee, M.D.*
Background/Aims The study proposed to evaluate the efficacy of anticancer drugs of intraarterial chemoinfusion and investigate prognostic factors influencing survival. Methods: A total of 127 patients diagnosed as having advanced hepatocellular carcinoma(HCC) of same stage (TNM stage IVa) from 1996 to 1998 were examined. Two intraarterial infusion chemotherapeutic regimens were employed: Adriamycin(Group I) and Cisplatin(Group II). Results: Overall survival was significantly diffrent(10.0 vs 5.7months) and favored Group I. By the univariate analysis, significant prognostic factors included: age, portal vein thrombosis(PVT), size(>5cm) and type of tumor, response rate (size & -fetoprotein) at 3 months after therapy, level of albumin, alkaline phosphatase, and total bilirubin. After repeated therapy, Group I showed better survival (14.0 vs 7.9 months), but there was no statistical difference in survival rate between two groups in the case of large size, PVT, and diffuse type. Conclusion: Group I showed better survival than Group II in advanced HCC of TNM stage IVa. But, considering prognostic factors, there was no significant difference in survival rate between two groups except small size or nodular type of HCC. TNM classification of stage IVa should be reconsidered to include prognostic factors influencing survival rate such as PVT, size and type of HCC.
Myoung Ki Sim, M.D., Do Young Kim, M.D., Jun Yong Park, M.D., Ja Kyung Kim, M.D.,
Sung Ai Kim, M.D., Sang Hoon Ahn, M.D., Chae Yoon Chon, M.D., Young Myoung Moon, M.D.,
Jong Yun Won, M.D.1, Do-Yun Lee, M.D.1, and Kwang-Hyub Han, M.D.
Background/Aims The aim of this study is to elucidate the efficacy of repeated hepatic arterial infusion chemotherapy (HAIC) and different chemotherapeutic regimens for treating patients having advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Methods: From Jan. 1999 and Dec. 2003, a total of 103 patients diagnosed as having HCC with PVTT, but without extrahepatic spreading, were enrolled in this study. They were stratified into two groups. Group I (67 patients) received intraarterial cisplatin (CDDP, 80 mg/m2 for 2 hours on Day 1), Group Ⅱ (36 patients) received intraarterial CDDP (60 mg/m2 for 2 hours on Day 2) and 5-fluorouracil (5-FU, 500 mg/m2 for 5 hours on Day 1-3). They were scheduled to receive at least three consecutive courses of the HAIC at 1 month intervals. Results: Among the 66 patients who completed the protocol, one (2.5%) and seven (17.5%) patients of group Ⅰ, and one (3.8%) and four (15.4%) of group Ⅱ, exhibited complete and partial responses, respectively. The median survival period of all the patients was 6 months. Group Ⅱ showed a tendency to improve the median survival compared to group Ⅰ (8.5 vs 5.0 months, respectively, P=0.45). The most common adverse reaction was nausea (58.2%). However, an elevation of the total bilirubin level was more frequent in Group Ⅰ than in Group Ⅱ (61.3% vs 20.7%, respectively, P<0.05). Conclusions: Repeated HAIC using CDDP achieved favorable results in a few patients with HCC with PVTT, and additional 5-FU may be useful. (Korean J Hepatol 2005;11:268-274)